AU2019270900B2 - Viral vectors exhibiting improved gene delivery properties - Google Patents

Viral vectors exhibiting improved gene delivery properties

Info

Publication number
AU2019270900B2
AU2019270900B2 AU2019270900A AU2019270900A AU2019270900B2 AU 2019270900 B2 AU2019270900 B2 AU 2019270900B2 AU 2019270900 A AU2019270900 A AU 2019270900A AU 2019270900 A AU2019270900 A AU 2019270900A AU 2019270900 B2 AU2019270900 B2 AU 2019270900B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
capsid polypeptide
viral
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019270900A
Other languages
English (en)
Other versions
AU2019270900A1 (en
Inventor
George M. Church
Eric KELSIC
Pierce OGDEN
Sam SINAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of AU2019270900A1 publication Critical patent/AU2019270900A1/en
Application granted granted Critical
Publication of AU2019270900B2 publication Critical patent/AU2019270900B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019270900A 2018-05-15 2019-05-08 Viral vectors exhibiting improved gene delivery properties Active AU2019270900B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671949P 2018-05-15 2018-05-15
US62/671,949 2018-05-15
PCT/US2019/031307 WO2019221992A1 (en) 2018-05-15 2019-05-08 Viral vectors exhibiting improved gene delivery properties

Publications (2)

Publication Number Publication Date
AU2019270900A1 AU2019270900A1 (en) 2020-10-15
AU2019270900B2 true AU2019270900B2 (en) 2026-03-12

Family

ID=68540740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019270900A Active AU2019270900B2 (en) 2018-05-15 2019-05-08 Viral vectors exhibiting improved gene delivery properties

Country Status (6)

Country Link
US (1) US12338267B2 (https=)
EP (1) EP3813845A4 (https=)
JP (2) JP2021522840A (https=)
AU (1) AU2019270900B2 (https=)
CA (1) CA3100066A1 (https=)
WO (1) WO2019221992A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461836A1 (en) 2017-09-28 2019-04-03 Universität zu Köln Mutated adeno-associated viral capsid proteins for chemical coupling of ligands, nanoparticles or drugs via thioether binding and production method thereof
EP4069856A1 (en) * 2019-12-04 2022-10-12 Sangamo Therapeutics, Inc. Novel compositions and methods for producing recombinant aav
EP4097121A1 (en) * 2020-01-29 2022-12-07 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
CN111349148A (zh) * 2020-03-13 2020-06-30 辉大(上海)生物科技有限公司 一种腺相关病毒载体及其用途
KR20230005941A (ko) * 2020-05-01 2023-01-10 트러스티스 오브 보스톤 칼리지 향상된 유전자 요법을 위한 아데노-관련 바이러스(aav)의 제어된 변형
CA3222914A1 (en) * 2021-06-23 2022-12-29 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
WO2023283962A1 (en) * 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
EP4508065A2 (en) * 2022-04-15 2025-02-19 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
EP4508228A2 (en) * 2022-04-15 2025-02-19 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
WO2026084101A1 (ko) * 2024-10-18 2026-04-23 주식회사 아바타테라퓨틱스 아데노연관바이러스 변이체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124724A1 (en) * 2007-04-09 2008-10-16 University Of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
WO2013170078A1 (en) * 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
WO2013173512A2 (en) * 2012-05-15 2013-11-21 University Of Florida Research Foundation, Inc. High-transduction-efficiency raav vectors, compositions, and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
CA2373110A1 (en) 2000-03-14 2001-09-20 Neurologix, Inc. Production of chimeric capsid vectors
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
JP7406783B2 (ja) * 2015-12-14 2023-12-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
WO2017147477A1 (en) * 2016-02-26 2017-08-31 University Of Florida Research Foundation, Inc. Aav heparin mutants that display significantly improved eye and brain transduction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124724A1 (en) * 2007-04-09 2008-10-16 University Of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
WO2013170078A1 (en) * 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
WO2013173512A2 (en) * 2012-05-15 2013-11-21 University Of Florida Research Foundation, Inc. High-transduction-efficiency raav vectors, compositions, and methods of use
US20140341852A1 (en) * 2012-05-15 2014-11-20 University Of Florida Research Foundation, Inc. Capsid-modified raav vector compositions and methods therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S R DE SILVA, P CHARBEL ISSA, M S SINGH, D M LIPINSKI, A O BARNEA-CRAMER, N J WALKER, A R BARNARD, M W HANKINS, R E MACLAREN: "Single residue AAV capsid mutation improves transduction of photoreceptors in the Abca4−/− mouse and bipolar cells in the rd1 mouse and human retina ex vivo", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 23, no. 11, 1 November 2016 (2016-11-01), GB, pages 767 - 774, XP055659010, ISSN: 0969-7128, DOI: 10.1038/gt.2016.54 *

Also Published As

Publication number Publication date
JP2024051082A (ja) 2024-04-10
JP7741575B2 (ja) 2025-09-18
WO2019221992A1 (en) 2019-11-21
US12338267B2 (en) 2025-06-24
JP2021522840A (ja) 2021-09-02
EP3813845A1 (en) 2021-05-05
EP3813845A4 (en) 2022-10-26
US20210230229A1 (en) 2021-07-29
AU2019270900A1 (en) 2020-10-15
CA3100066A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
AU2019270900B2 (en) Viral vectors exhibiting improved gene delivery properties
Bantel-Schaal et al. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses
US7419817B2 (en) Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
Huang et al. Characterization of the adeno-associated virus 1 and 6 sialic acid binding site
Bossis et al. Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles
AU2018291023B2 (en) AAV vector column purification methods
Samulski et al. AAV-mediated gene therapy for research and therapeutic purposes
Rayaprolu et al. Comparative analysis of adeno-associated virus capsid stability and dynamics
Kaludov et al. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography
JP6868572B2 (ja) アフィニティー精製工程を含む組換えアデノ随伴ウイルス粒子の精製
AU780231B2 (en) Virus vectors and methods of making and administering the same
US7588772B2 (en) AAV capsid library and AAV capsid proteins
US7851196B2 (en) Methods for purifying adeno-associated virus particles
US20030207439A1 (en) Large-scale recombinant adeno-associated virus (rAAV) production and purification
KR20190006951A (ko) 컬럼-기반 완전히 확장 가능한 rAAV 제조 공정
EP3310369B1 (en) Self-limiting viral vectors encoding nucleases
WO2008021140A2 (en) Recombinant aav production in mammalian cells
CN111808828B (zh) 腺相关病毒的分离纯化方法
Kochergin-Nikitsky et al. Tissue and cell-type-specific transduction using rAAV vectors in lung diseases
CA3223292A1 (en) Adeno-associated virus packaging systems
Yoon et al. Amino-terminal domain exchange redirects origin-specific interactions of adeno-associated virus rep78 in vitro
Romanovsky et al. Heparan sulfate proteoglycan affinity of adeno-associated virus vectors: Implications for retinal gene delivery
US20230013145A1 (en) Aav capsid-promoter interactions and cell selective gene expression
CN112218880A (zh) 逃避中和的肝趋向性重组aav6载体
WO2025054005A9 (en) Rep promoters for aav production